

AMENDMENT TO THE CLAIMS

Claims 1-4 (Cancelled)

5. (Previously Amended) An isolated KIAA0175 inhibitor wherein said inhibitor is an antisense molecule comprising the nucleic acid sequence of SEQ ID NO:1, wherein said antisense molecule is not longer than 25 nucleotides in length and is capable of inhibiting the expression of KIAA0175.

6. (Withdrawn) A method of decreasing the expression of KIAA0175 in a mammalian cell, comprising administering to said cell a KIAA0175 inhibitor of claim 1.

7. (Withdrawn) The method according to claim 6 wherein said KIAA0175 inhibitor is an anti-sense molecule comprising at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

8. (Withdrawn) A method of decreasing the expression of p21 in a mammalian cell, comprising administering to said cell a KIAA0175 inhibitor of claim 1.

9. (Withdrawn) The method according to claim 8 wherein said KIAA0175 inhibitor is an anti-sense molecule comprising at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

10. (Withdrawn) A method of decreasing the expression of p53 in a mammalian cell, comprising administering to said cell a KIAA0175 inhibitor of claim 1.

11. (Withdrawn) The method according to claim 10 wherein said KIAA0175 inhibitor is an anti-sense molecule comprising at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

12. (Withdrawn) A method for increasing the chemosensitivity and/or radiosensitivity of a mammalian cell, comprising administering to said mammalian cell a therapeutically effective amount of a KIAA0175 inhibitor of claim 1.

13. (Withdrawn) The method according to claim 12 wherein said KIAA0175 inhibitor is an anti-sense molecule comprising at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

14. (Withdrawn) The method of claim 12 wherein said mammalian cell is a tumor cell.

15. (Withdrawn) The method of claim 12 wherein said increase in chemosensitivity and/or radiosensitivity is determined by a measurement selected from the group consisting of measuring a reduction in γ -irradiation or hydroxyurea induced p53 or p21 protein levels, measuring a reduction in γ -irradiation or hydroxyurea induced cell cycle arrest and measuring an increase in γ -irradiation or hydroxyurea induced cell sensitization.

16. (Withdrawn) A method of reducing the side effects of cancer therapy, comprising administering to a mammal in need thereof a therapeutically effective amount of a KIAA0175 inhibitor of claim 1.

17. (Withdrawn) The method according to claim 16 wherein said KIAA0175 inhibitor is an anti-sense molecule comprising at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

18. (Withdrawn) A method of treating neoplastic disease in a mammal in need of said treatment, comprising administering to said mammal a KIAA0175 inhibitor of claim 1 such that said neoplastic disease is reduced in severity.

19. (Withdrawn) A method of decreasing the expression of KIAA0175 in a mammalian cell, comprising administering *ex vivo* to said cell a KIAA0175 inhibitor of claim 1.

20. (Currently Amended) A composition comprising a therapeutically effective amount of at least one KIAA0175 inhibitor in a pharmaceutically acceptable carrier, wherein at least one of said KIAA0175 inhibitors is a polynucleotide comprising an antisense molecule of SEQ ID NO:1 wherein said polynucleotide is not longer than 25 nucleotides in length and hybridizes specifically with SEQ ID NO:9.

21. (Original) The composition of claim 20, comprising two or more KIAA0175 inhibitors.

22. (Cancelled)

Claims 23-25(Cancelled)

26. (Original) The composition of claim 20 further comprising an inhibitor selected from the group consisting of an ATM inhibitor, a DNA-PK inhibitor and an ATR inhibitor.